Glioblastoma, IDH-Wildtype

subtype

Identifier: CI-CAN-00002779
Entity page: /cancer/glioblastoma-idh-wildtype ↗
Edges: 388

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Glioblastoma, IDH-Wildtype investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 85show all (up to 200)
→ investigated in trials for	Temozolomidesmall molecule 82 trials (28 active) · roll-up of the cancer and its descendants	—	—	Glioblastoma, IDH-Wildtype	82	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody

Glioblastoma, IDH-Wildtype studied in …STUDIED_INderived10 of 303show all (up to 200)
→ studied in	NCT05864534Phase 2 · active not recruiting Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma · condition mapped ONTOLOGY_EXACT · 303 trials mapped (84 active)	—	—	Gliosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05432804Phase 1/Phase 2 · recruiting Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment · condition mapped CURATED_BROADER · 303 trials mapped (84 active)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT03896568Phase 1 · recruiting MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma · condition mapped CURATED_BROADER · 303 trials mapped (84 active)	—	—	Gliosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ONTOLOGY_EXACT · 303 trials mapped (84 active)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT03174197Phase 1/Phase 2 · completed Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma · condition mapped ONTOLOGY_EXACT · 303 trials mapped (84 active)	—	—	Gliosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07708961Phase 2 · suspended Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma · condition mapped ONTOLOGY_EXACT · 303 trials mapped (84 active)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT03197506Phase 2 · active not recruiting Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma · condition mapped ONTOLOGY_EXACT · 303 trials mapped (84 active)	—	—	Gliosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07089641Phase 1 · recruiting ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial · condition mapped ONTOLOGY_EXACT · 303 trials mapped (84 active)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT03115333NA · active not recruiting DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma · condition mapped ONTOLOGY_EXACT · 303 trials mapped (84 active)	—	—	Gliosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05698524Phase 1 · recruiting A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma · condition mapped ONTOLOGY_EXACT · 303 trials mapped (84 active)	—	—	Gliosarcoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains